Predicted Effects of Treatment for HCV Infection Vary Among European Countries
- 1 October 2012
- journal article
- Published by Elsevier BV in Gastroenterology
- Vol. 143 (4), 974-985.e14
- https://doi.org/10.1053/j.gastro.2012.05.054
Abstract
No abstract availableFunding Information
- Janssen Pharmaceuticals
This publication has 69 references indexed in Scilit:
- Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1New England Journal of Medicine, 2012
- Boceprevir for Previously Treated Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2011
- Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease ProgressionGastroenterology, 2010
- Antiviral treatment for hepatitis C virus infection: Effectiveness at general population level in a highly endemic areaDigestive and Liver Disease, 2009
- Hepatitis C Infection Among Injecting Drug Users in England and Wales (1992-2006): There and Back Again?American Journal of Epidemiology, 2009
- Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2009
- HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortalityBMC Public Health, 2009
- Estimating the incidence, prevalence and clinical burden of hepatitis C over time in ItalyScandinavian Journal of Infectious Diseases, 2009
- Hepatitis C virus: laboratory surveillance in England and Wales, 1992–2004Epidemiology and Infection, 2006
- Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trialsGastroenterology, 1999